Mario Cauli, MD
Neurology · Jonesboro, ARNPI 1043273568
Payments from drug & device makers
Across 1,208 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impel Pharmaceuticals Inc.$6K
- Biogen$2K
- SK Life Science, Inc.$2K
- EMD Serono, Inc.$2K
- UCB, Inc.$1K
- Neurocrine Biosciences, Inc.$978
- plus $14K from 52 others
What the payments were for
- Consulting fees$5,14519%
- Speaking & faculty fees$3111%
- Travel & lodging$4972%
- Food & beverage$20,95177%
- Education$2611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,165 in reported general payments places this provider in the 80th percentile of 93 neurology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 37 | $340,336 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $294,056 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 16 | $291,082 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $248,429 |
| IngrezzaValbenazine Tosylate | 22 | $190,044 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 18 | $156,778 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $124,714 |
| VumerityDiroximel Fumarate | 13 | $118,456 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $67,097 |
| Aimovig AutoinjectorErenumab-Aooe | 66 | $62,271 |
| XcopriCenobamate | 50 | $59,721 |
| Nurtec OdtRimegepant Sulfate | 29 | $45,563 |
| Emgality PenGalcanezumab-Gnlm | 56 | $45,172 |
| Pregabalin | 633 | $17,992 |
| UbrelvyUbrogepant | 13 | $17,246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt | $570 | $336,64545 claims |
| CSL BehringPrivigen | $757 | $294,05636 claims |
| BiogenAvonex (4 Pack), Vumerity | $1,867 | $243,17026 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $978 | $199,88137 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $16 | $156,77818 claims |
| Grifols USA, LLCGamunex-C | $37 | $67,09712 claims |
| SK Life Science, Inc.Xcopri | $1,615 | $59,72150 claims |
| AbbVieUbrelvy, Savella | $962 | $24,80726 claims |
| UCB, Inc.Neupro, Nayzilam | $1,016 | $16,63523 claims |
| Eisai Inc.Fycompa | $546 | $13,78911 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $667 | $13,46511 claims |
| Amneal Pharmaceuticals LLCRytary | $310 | $12,29012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 neurology providers in Arkansas.
Other neurology in Jonesboro
- Ronald SouthJonesboro$59K
- Kenneth ChanJonesboro$20K
- Yuanyuan LongJonesboro$6K
- Bing BehrensJonesboro$5K
- Shari DesilvaRogers$5.7M
- Steve-Felix BelingaFort Smith$809K
- Richard PellegrinoHot Springs$573K
- Kathryn ChenaultSherwood$532K
- Kapil AryaLittle Rock$405K
- Margaret TremwelFayetteville$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.